Pharsight

1. Comtan patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5446194	ORION PHARMA	Pharmacologically active catechol derivatives	Oct, 2013 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6599530	ORION PHARMA	Oral compacted composition comprising catechol derivatives	Sep, 2018 (5 years ago)

Drugs and Companies using ENTACAPONE ingredient

Market Authorisation Date: 19 October, 1999

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg	11 Apr, 2007	1	16 Aug, 2012	14 Sep, 2018	Extinguished

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription

COMTAN family patents

2. Stalevo 100 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5446194	ORION PHARMA	Pharmacologically active catechol derivatives	Oct, 2013 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6797732	ORION PHARMA	Pharmaceutical composition comprising entracapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)
US6500867	ORION PHARMA	Pharmaceutical composition comprising entacapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)

Drugs and Companies using CARBIDOPA; ENTACAPONE; LEVODOPA ingredient

Market Authorisation Date: 11 June, 2003

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
12.5 mg, 50 mg and 200 mg	05 Aug, 2008	1	20 Nov, 2012	29 Jun, 2020	Extinguished Deferred
18.75 mg/75 mg/ 200 mg and 31.25 mg/125 mg/ 200 mg	19 May, 2009	1	20 Nov, 2012	29 Jun, 2020	Deferred
25/100/200 mg and 37.5/150/200 mg	29 Jun, 2007	1	10 May, 2012	29 Jun, 2020	Extinguished
50 mg/200 mg/ 200 mg	28 Aug, 2008	1			Deferred

Strength	Dosage	Availability
25MG;200MG;100MG	TABLET;ORAL	Prescription

STALEVO 100 family patents

3. Stalevo 125 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5446194	ORION PHARMA	Pharmacologically active catechol derivatives	Oct, 2013 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6797732	ORION PHARMA	Pharmaceutical composition comprising entracapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)
US6500867	ORION PHARMA	Pharmaceutical composition comprising entacapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)

Drugs and Companies using CARBIDOPA; ENTACAPONE; LEVODOPA ingredient

Market Authorisation Date: 11 June, 2003

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
12.5 mg, 50 mg and 200 mg	05 Aug, 2008	1	20 Nov, 2012	29 Jun, 2020	Extinguished Deferred
18.75 mg/75 mg/ 200 mg and 31.25 mg/125 mg/ 200 mg	19 May, 2009	1	20 Nov, 2012	29 Jun, 2020	Deferred
25/100/200 mg and 37.5/150/200 mg	29 Jun, 2007	1	10 May, 2012	29 Jun, 2020	Extinguished
50 mg/200 mg/ 200 mg	28 Aug, 2008	1			Deferred

Strength	Dosage	Availability
31.25MG;200MG;125MG	TABLET;ORAL	Prescription

STALEVO 125 family patents

4. Stalevo 150 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5446194	ORION PHARMA	Pharmacologically active catechol derivatives	Oct, 2013 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6797732	ORION PHARMA	Pharmaceutical composition comprising entracapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)
US6500867	ORION PHARMA	Pharmaceutical composition comprising entacapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)

Drugs and Companies using CARBIDOPA; ENTACAPONE; LEVODOPA ingredient

Market Authorisation Date: 11 June, 2003

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
12.5 mg, 50 mg and 200 mg	05 Aug, 2008	1	20 Nov, 2012	29 Jun, 2020	Extinguished Deferred
18.75 mg/75 mg/ 200 mg and 31.25 mg/125 mg/ 200 mg	19 May, 2009	1	20 Nov, 2012	29 Jun, 2020	Deferred
25/100/200 mg and 37.5/150/200 mg	29 Jun, 2007	1	10 May, 2012	29 Jun, 2020	Extinguished
50 mg/200 mg/ 200 mg	28 Aug, 2008	1			Deferred

Strength	Dosage	Availability
37.5MG;200MG;150MG	TABLET;ORAL	Prescription

STALEVO 150 family patents

5. Stalevo 200 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5446194	ORION PHARMA	Pharmacologically active catechol derivatives	Oct, 2013 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6500867	ORION PHARMA	Pharmaceutical composition comprising entacapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)
US6797732	ORION PHARMA	Pharmaceutical composition comprising entracapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)

Drugs and Companies using CARBIDOPA; ENTACAPONE; LEVODOPA ingredient

Market Authorisation Date: 11 June, 2003

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
12.5 mg, 50 mg and 200 mg	05 Aug, 2008	1	20 Nov, 2012	29 Jun, 2020	Extinguished Deferred
18.75 mg/75 mg/ 200 mg and 31.25 mg/125 mg/ 200 mg	19 May, 2009	1	20 Nov, 2012	29 Jun, 2020	Deferred
25/100/200 mg and 37.5/150/200 mg	29 Jun, 2007	1	10 May, 2012	29 Jun, 2020	Extinguished
50 mg/200 mg/ 200 mg	28 Aug, 2008	1			Deferred

Strength	Dosage	Availability
50MG;200MG;200MG	TABLET;ORAL	Prescription

STALEVO 200 family patents

6. Stalevo 50 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5446194	ORION PHARMA	Pharmacologically active catechol derivatives	Oct, 2013 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6797732	ORION PHARMA	Pharmaceutical composition comprising entracapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)
US6500867	ORION PHARMA	Pharmaceutical composition comprising entacapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)

Drugs and Companies using CARBIDOPA; ENTACAPONE; LEVODOPA ingredient

Market Authorisation Date: 11 June, 2003

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
12.5 mg, 50 mg and 200 mg	05 Aug, 2008	1	20 Nov, 2012	29 Jun, 2020	Extinguished Deferred
18.75 mg/75 mg/ 200 mg and 31.25 mg/125 mg/ 200 mg	19 May, 2009	1	20 Nov, 2012	29 Jun, 2020	Deferred
25/100/200 mg and 37.5/150/200 mg	29 Jun, 2007	1	10 May, 2012	29 Jun, 2020	Extinguished
50 mg/200 mg/ 200 mg	28 Aug, 2008	1			Deferred

Strength	Dosage	Availability
12.5MG;200MG;50MG	TABLET;ORAL	Prescription

STALEVO 50 family patents

7. Stalevo 75 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5446194	ORION PHARMA	Pharmacologically active catechol derivatives	Oct, 2013 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6797732	ORION PHARMA	Pharmaceutical composition comprising entracapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)
US6500867	ORION PHARMA	Pharmaceutical composition comprising entacapone, levodopa, and carbidopa	Jun, 2020 (3 years ago)

Drugs and Companies using CARBIDOPA; ENTACAPONE; LEVODOPA ingredient

Market Authorisation Date: 11 June, 2003

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

Pharsight

Orion Pharma patents expiration

1. Comtan patents expiration

COMTAN family patents

2. Stalevo 100 patents expiration

STALEVO 100 family patents

3. Stalevo 125 patents expiration

STALEVO 125 family patents

4. Stalevo 150 patents expiration

STALEVO 150 family patents

5. Stalevo 200 patents expiration

STALEVO 200 family patents

6. Stalevo 50 patents expiration

STALEVO 50 family patents

7. Stalevo 75 patents expiration

STALEVO 75 family patents

Related content